Background: The use of systemic corticosteroids is discouraged in major psoriasis treatment guidelines.
Purpose: Our objective was to assess how often systemic corticosteroids are prescribed for psoriasis and trends in their use over time.
Methods: We used National Ambulatory Medical Care Survey (NAMCS) data to determine the systemic medications prescribed for psoriasis from 1989 to 2010. We confirmed the findings by analysis of 2003-2007 MarketScan Medicaid data.
Results: Systemic corticosteroids were prescribed at 650,000 (95% CI 380,000-920,000) of 21,000,000 psoriasis visits; 93% of these visits were to dermatologists. Of the top nine systemic medications listed at psoriasis visits, three of them were corticosteroids. Corticosteroids were the second most commonly prescribed systemic medication for psoriasis. No significant change in the use of systemic corticosteroids for psoriasis over time was observed (p = .27). In the MarketScan data, prednisone was prescribed more commonly than either methotrexate or etanercept.
Limitations: Corticosteroid doses and the length of treatment were not recorded in the NAMCS data.
Conclusions: Systemic corticosteroids are among the most common systemic treatments used for psoriasis despite current guidelines. Data are acutely needed on the risks and benefits so that physicians and patients can make evidence-based decisions about their use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2310/7750.2013.13126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatable Trait Guided Asthma Management: A Feasibility Study.
Respirology
March 2025
College of Health and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia.
Background And Objectives: Treatable trait-based personalised medicine improves outcomes in severe asthma clinics. We assessed the feasibility of a randomised controlled trial (RCT) of protocolised treatable trait-guided asthma management in patients not under a severe asthma clinic.
Methods: Ten week single-group cohort study.
Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies.
J Cutan Med Surg
March 2025
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Mycosis fungoides (MF) and Sézary syndrome (SS) are subtypes of cutaneous T-cell lymphoma with numerous topical and systemic therapies. Early-stage MF can be managed with topical corticosteroids, mechlorethamine, and phototherapy. However, patients are often non-responsive to topical therapies, thus requiring systemic therapies.
View Article and Find Full Text PDFIgG4-related disease: lessons from the first 20 years.
Rheumatology (Oxford)
March 2025
Harvard Medical School, Division of Rheumatology, Allergy, and Immunology, The Edward A. Fox Chair in Medicine, Massachusetts General Hospital, Executive Chairman, The IgG4ward! Foundation, Boston, MA, USA.
Immunoglobulin G4-related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory disease that is believed but not confirmed to have an autoimmune origin. Since its discovery nearly two decades ago, our understanding of its pathophysiology and clinical manifestations has grown substantially. Early diagnosis and treatment of this elusive disease can prevent substantial organ damage from end-stage fibrosis.
View Article and Find Full Text PDFDiagnosis of Aspergillus Osteomyelitis of the Clivus and Sella Turcica in a Patient With Type 2 Diabetes and a History of Prolonged Intranasal Corticosteroid Use.
Cureus
February 2025
Infectious Diseases and Global Medicine, Malcom Randall Veterans Affairs Medical Center, University of Florida College of Medicine, Gainesville, USA.
A 69-year-old immunocompetent male with uncontrolled type 2 diabetes mellitus (T2DM) presented with atypical left-sided headaches, diverging from his usual migraine pattern. Historically experiencing right-sided migraines, the patient's shift to left-sided headaches occurred after a month of using fluticasone for cold-like symptoms and potential mold exposure at home. Computed tomography (CT) and magnetic resonance imaging (MRI) suggested the diagnosis of skull base osteomyelitis.
View Article and Find Full Text PDFCyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices.
Pediatr Rheumatol Online J
March 2025
Department of Pediatric Nephrology, Gazi University Faculty of Medicine, Ankara, Turkey.
Background: Cyclophosphamide (CYC) is an inactive alkylating agent that transforms the alkyl radicals into other molecules and is used in combination with systemic corticosteroids in the treatment of many childhood rheumatic diseases, such as systemic lupus erythematosus (SLE), and ANCA-associated vasculitis (AAV). In recent years, rituximab (RTX), a B-cell-targeting anti-CD20 monoclonal antibody, has emerged as a new alternative treatment modality over CYC for induction therapy of childhood-onset rheumatic diseases. Clinicians adopt different practices for using CYC particularly in relation to indications, posology, pre-treatment laboratory work-up, post-treatment follow-up, and screening pre- and post-treatment vaccination status.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!